2024-518172-31-01招募中3 期
ERIS: EGFR-Mutated Lung Cancer in Randomized Investigator-Initiated Study
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- Region Skane
- 入组人数
- 200
- 试验地点
- 10
- 主要终点
- Progression-free survival (PFS)
研究概览
简要总结
To evaluate the optimal sequence of EGFR-inhibitors.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Written informed consent
- •Negative pregnancy test (blood or urine test)
- •Histological or cytological diagnosis of NSCLC.
- •Clinical stage III/IV disease or a recurrence not amenable for curative treatment intention.
- •Measurable disease according to RECIST 1.1 criteria or equivalent/modified criteria.
- •Any WHO PS.
- •Age 18 years or older.
- •EGFR-mutation in tumor (in cases where tumor tissue is not available for mutation analysis, circulating tumour-DNA (ctDNA) in plasma may serve as inclusion criteria).
- •Treatment-naive with regard to TKI’s.
- •For fertile participants, adequate contraception should be used; intrauterine device, bilateral tubal occlusion, vasectomy or abstinence (a reduced effect of hormonal contraception methods due to the drugs cannot be excluded). Pregnancy should be avoided during treatment and the first 4 months following treatment discontinuation.
排除标准
- •Condition incompatible with the study or with the planned treatment.
- •Gastrointestinal conditions incompatible with swallowing or precluding absorption of the study drug.
- •Pregnancy or refusal to use contraceptives.
- •Abnormal findings of blood chemistry not compatible with the study drug according to investigator.
- •History of hypersensitivity to the study drug (or drugs with a similar chemical structure or class) or any excipients.
- •Co-enrolment in other interventional trial if incompatible with ERIS according to investigator (e.g. due to potential drug interactions).
- •Severe hepatic impairment/renal function incompatible with study drug according to investigator.
- •Hereditary conditions with galactose intolerance, total lactase deficiency or glucose -galactose malabsorption.
- •Congenital long QT syndrome.
- •Judgment by the investigator that the subject should not participate in the study, e.g., if the subject is unlikely to comply with study procedures, restrictions and requirements.
- •Present second primary malignancy with metastatic potential.
- •Intake of hypericum perforatum (intake must be interrupted before start of study treatment).
- •All subjects should avoid concomitant use of medications with known interaction with planned treatment, whenever feasible. If the administration of a medication interacts with any of the three investigational treatments and cannot be exchanged or managed in order to avoid interactions the patient is excluded from the trial.
- •Any evidence of severe or uncontrolled systemic diseases which in the investigator’s opinion makes it undesirable for the subject to participate in the trial or which would jeopardise compliance with the protocol. Screening for chronic conditions is not required.
结局指标
主要结局
Progression-free survival (PFS)
Progression-free survival (PFS)
次要结局
- Time to treatment failure (TTF) of EGFR-inhibitor sequence (total time on TKI)
- Overall survival (OS)
- Objective response rate (ORR) in first line and the entire sequence of treatment with EGFR-inhibitors
- Disease control rate in (DCR) first line and the entire sequence of treatment with EGFR-inhibitors
- Adverse events (AE)
- Quality of life (QoL) as assessed through Lung Cancer Symptom Scale (LCSS)
- Tumor-derived cell-free DNA, i.e. ctDNA, will be analyzed in plasma (and in some cases other fluids, e.g. pleural effusion) to search for potential resistance mechanisms to EGFR-TKIs, to identify early progression and to monitor treatment response. The sensitizing EGFR-mutation, EGFR T790M that confer EGFR-TKI resistance and possibly other tumor mutations, or genetic alterations will be analyzed, either alterations detected in pre-treatment tumor tissue or alterations being screened for in liqui
- Proximity Extension Analysis (PEA) protein profiling and RNA expression analysis will be performed on tumor tissue. Obtained markers will subsequently be analyzed with exploratory bioinformatics to set up signaling networks possible to follow longitudinally during the disease course. Furthermore, biomarker candidates may be validated as potential drug candidates.
- Bypass signaling is one reason of TKI-resistance. On tumor biopsies prior treatment, bypass signaling mechanisms with focus on Eph signaling components will be analyzed in situ. Upon relapse, the same reactions will be carried out on re-biopsies and differences will be evaluated in the context of response to EGFR-TKI.
- Exosomes isolated from plasma and other body fluids will be profiled for mRNA, miRNA and proteins that could be potential key players in resistance mechanisms.
- Copy number alterations analysis performed on tumor specimen prior treatment and when possible, on tumor re-biopsies at time of progression.
- Tumor mutational burden (TMB, defined as mutations/megabase) on tumor tissue and potentially on longitudinally assembled blood will be evaluated as a potential marker of resistance and treatment response.
研究者
Maria Planck
Scientific
Region Skane
研究点 (10)
Loading locations...
相似试验
Unknown
不适用
Human EGFR Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method)Non Small Cell Lung CancerEGFR-TKI Resistant MutationEGFR-TKI Sensitizing MutationNCT02661009GenoSaber1,000
招募中
3 期
EGFR-mutated Lung Cancer in Randomized Investigator-Initiated StudyNon-Small Cell Lung CancerNCT06486142Region Skane200
进行中（未招募）
1 期
Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)Metastatic Non Small Cell Lung CancerNCT04743505Washington University School of Medicine27
终止
1 期
Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLCLung Cancer, Nonsmall CellNCT02991651Io Therapeutics12
Unknown
不适用
Mutations in the Epidermal Growth Factor Receptor(EGFR) Gene in Non-Small Cell Lung Carcinoma (NSCLC) and the Relation to Response of Treatment With ErlotinibNon-Small Cell Lung CancerNCT00815971Aarhus University Hospital300